N-TproBNP as biomarker in systemic sclerosis

Clinical Reviews in Allergy and Immunology

Volumn 43, Issue 3, 2012, Pages 292-301

  Schioppo, Tommaso ^a   Artusi, Carolina ^a   Ciavarella, Teresa ^a   Ingegnoli, Francesca ^a   Murgo, Antonella ^a   Zeni, Silvana ^a   Chighizola, Cecilia ^a   Meroni, Pier Luigi ^a,b  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

Author keywords

Biomarker; Interstitial lung disease; N TproBNP; Pulmonary arterial hypertension; Systemic sclerosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ARTICLE; COHORT ANALYSIS; GENE EXPRESSION; HEART FAILURE; HOMEOSTASIS; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG VASCULAR RESISTANCE; PULMONARY HYPERTENSION; SCLERODERMA; SENSITIVITY AND SPECIFICITY; SYSTEMIC SCLEROSIS; THORAX RADIOGRAPHY;

BIOLOGICAL MARKERS; HUMANS; NATRIURETIC PEPTIDES; NEUROTRANSMITTER AGENTS; SCLERODERMA, SYSTEMIC;

EID: 84871660172     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-012-8312-4     Document Type: Article

References (73)

1. Geyer M, Muller-Ladner U (2011) The pathogenesis of systemic sclerosis revisited. Clin Rev Allergy Immunol 40(2):92-103
2. Yap LB, Mukerjee D, Timms PM, Ashrafian H, Coghlan JG (2004) Natriuretic peptides, respiratory disease, and the right heart. Chest 126(4):1330-1336 (Pubitemid 39391268)
3. Hall C (2004) Essential biochemistry and physiology of (NT-pro) BNP. Eur J Heart Fail 6(3):257-260 (Pubitemid 38253043)
4. Wilkins MR, Redondo J, Brown LA (1997) The natriuretic-peptide family. Lancet 349(9061):1307-1310 (Pubitemid 27192482)
5. Helal I, Belhadj R, Mohseni A et al (2010) Clinical significance of N-Terminal pro-B-Type natriuretic peptide (NT-proBNP) in hemodialysis patients. Saudi J Kidney Dis Transpl 21(2):262-268
6. Silvers SM, Howell JM, Kosowsky JM, Rokos IC, Jagoda AS (2007) Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with acute heart failure syndromes. Ann Emerg Med 49(5):627-669 (Pubitemid 46601692)
7. Carpenter CR, Keim SM, Worster A, Rosen P (2012) Brain natriuretic peptide in the evaluation of emergency department dyspnea: is there a role? J Emerg Med 42(2):197-205
8. Maisel AS, Krishnaswamy P, Nowak RM et al (2002) Rapid measurement of B-Type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347(3):161-167 (Pubitemid 34764819)
9. Harrison A, Morrison LK, Krishnaswamy P et al (2002) B-Type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 39(2):131-138 (Pubitemid 34118942)
10. Doust JA, Pietrzak E, Dobson A, Glasziou P (2005) How well does B-Type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 330(7492):625
11. Hartmann F, Packer M, Coats AJ et al (2004) Prognostic impact of plasma N-Terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 110(13):1780-1786 (Pubitemid 39302655)
12. Lainchbury JG, Troughton RW, Frampton CM et al (2006) NTproBNP-guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trial. Eur J Heart Fail 8:532-538
13. Januzzi JL Jr (2012) The role of natriuretic peptide testing in guiding chronic heart failure management: review of available data and recommendations for use. Arch Cardiovasc Dis 105(1):40-50
14. Pimenta JM, Almeida R, Araujo JP et al (2007) Amino terminal Btype natriuretic peptide, renal function, and prognosis in acute heart failure: a hospital cohort study. J Card Fail 13(4):275-280 (Pubitemid 46756339)
15. Wu AH, Omland T, Wold Knudsen C et al (2005) Relationship of B-Type natriuretic peptide and anemia in patients with and without heart failure: a substudy from the Breathing Not Properly (BNP) Multinational Study. Am J Hematol 80(3):174-180 (Pubitemid 41579538)
16. Palazzuoli A, Silverberg DS, Iovine F et al (2007) Effects of betaerythropoietin treatment on left ventricular remodeling, systolic function, and B-Type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J 154(4):645.e9-15
17. Das SR, Abdullah SM, Leonard D et al (2008) Association between renal function and circulating levels of natriuretic peptides (from the Dallas Heart Study). Am J Cardiol 102(10):1394-1398
18. Palazzuoli A, Gallotta M, Quatrini I, Nuti R (2010) Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure. Vasc Health Risk Manag 6:411-418
19. Galie N, Torbicki A, Barst R et al (2004) Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 25(24):2243-2278
20. Mukerjee D, St George D, Coleiro B et al (2003) Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 62:1088-1093 (Pubitemid 37323574)
21. Campo A, Mathai SC, Le Pavec J et al (2010) Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 182(2):252-260
22. Steen V, Medsger TA Jr (2003) Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 48(2):516-522 (Pubitemid 36278021)
23. Steen VD (2008) The many faces of scleroderma. Rheum Dis Clin North Am 34(1):1-15 (Pubitemid 351329460)
24. McLaughlin VV, Archer SL, Badesch DB et al (2009) ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 53 (17):1573-1619
25. Miyamoto S, Nagaya N, Satoh T et al (2000) Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161(2 Pt 1):487-492 (Pubitemid 30129457)
26. Williams MH, Das C, Handler CE et al (2006) Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 92(7):926-932 (Pubitemid 43974055)
27. Mukerjee D, St George D, Knight C et al (2004) Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) 43 (4):461-466 (Pubitemid 38489363)
28. Dimitroulas T, Giannakoulas G, Karvounis H et al (2007) Neurohormonal activation in patients with systemic sclerosis-related pulmonary arterial hypertension. Int J Cardiol 121(1):135-137 (Pubitemid 47285373)
29. Choi HJ, Shin YK, Lee HJ et al (2008) The clinical significance of serum N-Terminal pro-brain natriuretic peptide in systemic sclerosis patients. Clin Rheumatol 27(4):437-442 (Pubitemid 351404297)
30. Ciurzynski M, Bienias P, Lichodziejewska B et al (2008) Noninvasive diagnostic and functional evaluation of cardiac involvement in patients with systemic sclerosis. Clin Rheumatol 27 (8):991-997
31. Williams MH, Handler CE, Akram R et al (2006) Role of Nterminal brain natriuretic peptide (N-TproBNP) in sclerodermaassociated pulmonary arterial hypertension. Eur Heart J 27 (12):1485-1494 (Pubitemid 43998084)
32. Elshamy HA, Ibrahim SE, Farouk HM, Moustafa AA, Aly IM, Osman WM (2011) N-Terminal pro-brain natriuretic peptide in systemic sclerosis: new insights. Eur J Dermatol 21(5):686-690
33. Oravec RM, Bredemeier M, Laurino CC et al (2010) NT-proBNP levels in systemic sclerosis: association with clinical and laboratory abnormalities. Clin Biochem 43(9):745-749
34. Allanore Y, Meune C (2009) N-Terminal pro brain natriuretic peptide: the new cornerstone of cardiovascular assessment in systemic sclerosis. Clin Exp Rheumatol 27(3 Suppl 54):59-63
35. Allanore Y, Borderie D, Avouac J et al (2008) High N-Terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 58(1):284-291
36. Dimitroulas T, Giannakoulas G, Papadopoulou K et al (2010) Left atrial volume and N-Terminal pro-B type natriuretic peptide are associated with elevated pulmonary artery pressure in patients with systemic sclerosis. Clin Rheumatol 29(9):957-964
37. Mathai SC, Bueso M, Hummers LK et al (2010) Disproportionate elevation of N-Terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension. Eur Respir J 35 (1):95-104
38. Dimitroulas T, Giannakoulas G, Karvounis H et al (2008) Nterminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension. Clin Rheumatol 27(5):655-658
39. Simeoni S, Lippi G, Puccetti A et al (2008) N-Terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH. Rheumatol Int 28(7):657-660
40. Hayakawa I, Shirasaki F, Hirano T et al (2006) Successful treatment with sildenafil in systemic sclerosis patients with isolated pulmonary arterial hypertension: two case reports. Rheumatol Int 26(3):270-273 (Pubitemid 41830988)
41. Kahan A, Allanore Y (2006) Primary myocardial involvement in systemic sclerosis. Rheumatology (Oxford) 45(Suppl 4):iv14-iv17 (Pubitemid 44446757)
42. Perera A, Fertig N, Lucas M et al (2007) Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-Topoisomerase I antibody. Arthritis Rheum 56(8):2740-2746 (Pubitemid 47237293)
43. Hanke K, Dahnrich C, Bruckner CS et al (2009) Diagnostic value of anti-Topoisomerase I antibodies in a large monocentric cohort. Arthritis Res Ther 11(1):R28
44. Arnett FC, Reveille JD, Goldstein R et al (1996) Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. Arthritis Rheum 39(7):1151-1160 (Pubitemid 26240228)
45. Tormey VJ, Bunn CC, Denton CP, Black CM (2001) Antifibrillarin antibodies in systemic sclerosis. Rheumatology (Oxford) 40(10):1157-1162
46. Champion HC (2008) The heart in scleroderma. Rheum Dis Clin North Am 34(1):181-190, viii (Pubitemid 351329461)
47. Allanore Y, Meune C, Vonk MC et al (2010) Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis 69(1):218-221
48. de Groote P, Gressin V, Hachulla E et al (2008) Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis 67(1):31-36
49. Poanta L, Dadu R, Tiboc C, Rednic S, Dumitrascu D (2009) Systolic and diastolic function in patients with systemic sclerosis. Eur J Intern Med 20(4):378-382
50. Meune C, Allanore Y, Pascal O et al (2005) Myocardial contractility is early affected in systemic sclerosis: a tissue Doppler echocardiography study. Eur J Echocardiogr 6(5):351-357 (Pubitemid 41258927)
51. Allanore Y, Meune C, Vignaux O, Weber S, Legmann P, Kahan A (2006) Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and Tissue-Doppler echography study. J Rheumatol 33(12):2464-2469 (Pubitemid 46067827)
52. Czirjak L, Kumanovics G, Varju C et al (2008) Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 67(1):59-63
53. Meune C, Vignaux O, Kahan A, Allanore Y (2010) Heart involvement in systemic sclerosis: evolving concept and diagnostic methodologies. Arch Cardiovasc Dis 103:46-52
54. Allanore Y, Wahbi K, Borderie D, Weber S, Kahan A, Meune C (2009) N-Terminal pro-brain natriuretic peptide in systemic sclerosis: a new cornerstone of cardiovascular assessment? Ann Rheum Dis 68(12):1885-1889
55. Montagnana M, Lippi G, Volpe A et al (2006) Evaluation of cardiac laboratory markers in patients with systemic sclerosis. Clin Biochem 39(9):913-917 (Pubitemid 44363080)
56. Dimitroulas T, Giannakoulas G, Papadopoulou K et al (2010) Early detection of cardiac involvement in systemic sclerosis assessed by tissue-Doppler echocardiography: relationship with neurohormonal activation and endothelial dysfunction. J Rheumatol 37(5):993-999
57. Bussone G, Mouthon L (2011) Interstitial lung disease in systemic sclerosis. Autoimmun Rev 10(5):248-255
58. Ferri C, Valentini G, Cozzi F et al (2002) Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 81(2):139-153 (Pubitemid 34218569)
59. Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 66(7):940-944 (Pubitemid 46999798)
60. Nihtyanova SI, Denton CP (2010) Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol 6(2):112-116
61. Steen VD, Conte C, Owens GR, Medsger TA Jr (1994) Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 37 (9):1283-1289 (Pubitemid 24320744)
62. Tashkin DP, Elashoff R, Clements PJ et al (2007) Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176(10):1026-1034 (Pubitemid 350127847)
63. Hoyles RK, Ellis RW, Wellsbury J et al (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54(12):3962-3970 (Pubitemid 44955900)
64. Takahashi H, Kuroki Y, Tanaka H et al (2000) Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis. Am J Respir Crit Care Med 162(1):258-263 (Pubitemid 30469830)
65. Yanaba K, Hasegawa M, Takehara K, Sato S (2004) Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. J Rheumatol 31(6):1112-1120 (Pubitemid 38715886)
66. Bonella F, Volpe A, Caramaschi P et al (2011) Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement. Sarcoidosis Vasc Diffuse Lung Dis 28 (1):27-33
67. (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23(5):581-590
68. Czirjak L, Foeldvari I, Muller-Ladner U (2008) Skin involvement in systemic sclerosis. Rheumatology (Oxford) 47(Suppl 5):v44-v45
69. Rodnan GP, Lipinski E, Luksick J (1979) Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 22(2):130-140 (Pubitemid 9156666)
70. Moinzadeh P, Denton CP, Abraham D et al (2012) Biomarkers for skin involvement and fibrotic activity in scleroderma. J Eur Acad Dermatol Venereol 26(3):267-276
71. Carlo-Stella N, Belloli L, Biondi ML, Marasini B (2009) Serum Nterminal pro-brain natriuretic peptide, a marker of skin thickness in systemic sclerosis? Clin Rheumatol 28(2):241-242
72. LeRoy EC, Black C, Fleischmajer R et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15(2):202-205 (Pubitemid 18073738)
73. Vonk D, Coghlan G, Bonderman D et al (2010) The DETECT study: a two-stage, prospective, observational, cohort study in scleroderma patients to evaluate screening tests and the incidence of pulmonary arterial hypertension and pulmonary hypertension. Clin Exp Rheumatol 28(Supp):55